Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression

• Julia T. Geyer,
• Elizabeth Margolskee,
• Spencer A. Krichevsky,
• Daniele Cattaneo,
• Leonardo Boiocchi,
• Paola Ronchi,
• Francesca Lunghi,
• Joseph M. Scandura,
• Maurilio Ponzoni,
• Robert P. Hasserjian,
• Umberto Gianelli,
• Alessandra Iurlo,
• Attilio Orazi

Affiliations

Julia T. Geyer

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

Elizabeth Margolskee

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

Spencer A. Krichevsky

Department of Medicine, Weill Cornell Medicine, New York, NY, USA

Daniele Cattaneo

Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Leonardo Boiocchi

Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Paola Ronchi

IRCCS San Raffaele Scientific Institute, Milan, Italy

Francesca Lunghi

IRCCS San Raffaele Scientific Institute, Milan, Italy

Joseph M. Scandura

Department of Medicine, Weill Cornell Medicine, New York, NY, USA

Maurilio Ponzoni

IRCCS San Raffaele Scientific Institute, Milan, Italy

Robert P. Hasserjian

Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Umberto Gianelli

Division of Pathology, Department of Pathophysiology and Transplantation, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Alessandra Iurlo

Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Attilio Orazi

Department of Pathology, Texas Tech University, El Paso, TX, USA